Overview

Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This a prospective, single-arm, multi-institutional, open label, phase 2 trial evaluating the effects of induction chemo-immunotherapy, followed by radioimmunotherapy, followed by consolidation immunotherapy in patients with locally advanced squamous cell carcinoma of the larynx who are candidates for organ preservation.
Phase:
Phase 2
Details
Lead Sponsor:
Latin American Cooperative Oncology Group
Treatments:
Carboplatin
Immunologic Factors
Paclitaxel
Pembrolizumab